Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 275.36M | 263.71M | 216.17M | 292.89M | 216.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 275.36M | 263.71M | 216.17M | 292.89M | 216.83M |
| Cost of Revenue | 93.07M | 84.12M | 74.83M | 70.10M | 69.33M |
| Gross Profit | 182.29M | 179.60M | 141.35M | 222.78M | 147.51M |
| SG&A Expenses | 129.13M | 120.31M | 104.75M | 104.55M | 93.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 256.04M | 236.79M | 210.89M | 204.48M | 184.19M |
| Operating Income | 19.32M | 26.93M | 5.28M | 88.41M | 32.64M |
| Income Before Tax | 16.87M | -614.00K | -644.00K | 81.96M | 24.33M |
| Income Tax Expenses | 1.62M | 23.00K | -134.00K | -- | -- |
| Earnings from Continuing Operations | 15.25M | -637.00K | -510.00K | 81.96M | 24.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.25M | -637.00K | -510.00K | 81.96M | 24.33M |
| EBIT | 19.32M | 26.93M | 5.28M | 88.41M | 32.64M |
| EBITDA | 25.92M | 33.46M | 10.35M | 92.70M | 37.51M |
| EPS Basic | 0.05 | 0.00 | 0.00 | 0.29 | 0.09 |
| Normalized Basic EPS | 0.04 | 0.05 | 0.00 | 0.19 | 0.05 |
| EPS Diluted | 0.05 | 0.00 | 0.00 | 0.28 | 0.08 |
| Normalized Diluted EPS | 0.04 | 0.05 | 0.00 | 0.18 | 0.05 |
| Average Basic Shares Outstanding | 283.89M | 282.89M | 282.56M | 282.22M | 282.10M |
| Average Diluted Shares Outstanding | 295.14M | 282.89M | 282.56M | 296.09M | 297.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |